Home » Biovail, GSK Accused of Generic Wellbutrin Delay
Biovail, GSK Accused of Generic Wellbutrin Delay
December 18, 2009
An employee benefit plan has filed a motion to certify a class action against Biovail and GlaxoSmithKline (GSK), alleging the companies conspired to delay
entry of a generic form of the antidepressant Wellbutrin XL.